Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Androstanolone→

Androstanolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
521-18-6
Molecular formula
C19H30O2
Molecular weight
290.4 g/mol
Drug class
Dihydrotestosterone (DHT)non-aromatisable androgen receptor agonist
Mechanism of action
Binds and activates androgen receptors, regulating androgen-responsive gene transcription in target tissues. Unlike testosterone, dihydrotestosterone is not aromatised to oestradiol.
Indications / reported uses
  • Historically used in selected countries for androgen replacement in male hypogonadism or specific androgen-deficiency states using topical formulations; current availability and authorised indication require local verification

Sources: NLM MeSH — Androstanolone (dihydrotestosterone) · PubMed — Dihydrotestosterone pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Androstanolone Environmental Risk Assessment (ERA) (the Androstanolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.